

AZ LIFE dac

Solvency and Financial Condition Report

As at December 31, 2017

Summary.....	3
A. BUSINESS AND PERFORMANCE.....	5
A.1 Business and external environment.....	5
A.2 Performance from underwriting activities.....	6
A.3 Performance from investment activities.....	7
A.4 Performance of other activities	7
A.5 Any other information.....	8
B. SYSTEM OF GOVERNANCE.....	8
B.1.1 Overview.....	8
B.1.2 Main Changes in Governance Structure.....	13
B.1.3 Remuneration Policy and Practices.....	13
B.1.4 Material Transactions.....	14
B.2 'Fit and Proper' Requirements	14
B.3 RISK MANAGEMENT SYSTEM	15
B.4 ORSA.....	18
B.5 Internal Control System.....	20
B.6 Internal Audit Function	20
B.7 Risk culture	20
B.8 Compliance Function.....	21
B.9 Actuarial Function	21
B.10 Outsourcing	22
B.11 Adequacy of the System of Governance	23
C. RISK PROFILE.....	23
C.1 Underwriting Risk	23
C.2 Market Risk.....	24
C.3 Credit Risk.....	24
C.4 Liquidity Risk.....	25
C.5 Operational Risk	25
C.5 Other Material Risks.....	26
C.7 Other Information	27
D. VALUATION FOR SOLVENCY PURPOSE	28
D.1 Assets	28
D.1.1 Property, plant and equipment.....	28
D.1.2 Government Bonds	28
D.1.3 Deposit other than cash equivalents	29
D.1.4 Assets held for index-linked and unit-linked contracts.....	29

D.1.5 Reinsurance recoverables from: Life index-linked and unit-linked	29
D.1.6 Insurance and intermediaries receivables	29
D.1.7 Receivables (trade, not insurance).....	29
D.1.8 Cash and cash equivalents	30
D.2 Technical Provision.....	30
D.3 Other Liabilities	31
D.3.1 Deferred Tax Liabilities.....	31
D.3.2 Insurance & intermediaries payables	31
D.3.3 Reinsurance payables.....	31
D.3.4 Payables (trade, not insurance)	31
D.3.5 Others.....	32
D.4 Alternative methods of valuation	32
D.5 Any other information	32
E. CAPITAL MANAGEMENT.....	32
E.1 Own Funds	32
E.1.1 Objectives, policies and processes employed for managing own funds	32
E.1.2 Analysis and details of own funds items	33
E.1.3 Material differences between equity as shown in AZ Life’s financial statements and the excess of assets over liabilities as calculated for solvency purposes.....	33
E.1.4 Basic own funds subject to transitional arrangements	33
E.1.5 Ancillary own funds	34
E.1.6 Items deducted from own funds	34
E.1.7 Own funds.....	34
E.2 Solvency Capital Requirement and Minimum Capital Requirement.....	34
E.2.1 SCR and MCR – Year End 2016-2017	34
E.2.2 SCR Split by risk module	34
E.2.3 Standard Formula Simplification	34
E.2.4 Specific parameters of the Standard Formula.....	34
E.2.5 Capital Add-ons.....	35
E.2.6 MCR Input.....	35
E.3 Use of the duration-based equity risk sub-module in the calculation of the Solvency Capital Requirement.....	35
E.4 Internal Model Information.....	35
E.5 Non-compliance with the Minimum Capital Requirement and noncompliance with the Solvency Capital Requirement.....	35
E.6 Any other information	35
APPENDIX 1 – REPORTING TEMPLATES.....	36

Summary

The new European regulatory regime for insurance companies, also known as Solvency II, came into force with effect from 1st January 2016. Such regime requires new reporting and public disclosure arrangements some of which is to be published on the Company's website, as appropriate. The Company's first Solvency and Financial Condition Report ("SFCR") was produced during 2017.

The content of this SFCR is prescribed by the regulation and contains the following sections: Business and Performance, System of Governance, Risk Profile, Valuation for Solvency Purposes and Capital Management. The responsibility of public disclosure is ultimately held by the Board of Directors (the "Board") as support by other functions of the Company in order monitor and manage the business.

The Company's business model as a life assurance Company is to establish and manage unit-linked policies which are sold cross-border into the Italian market, under the freedom of establishment regime. The company has a distribution agreement in place with one single distributor, namely Azimut Financial Insurance, which is part of Azimut Group. The business continued growing and the level of the written premiums in 2017 has been maintained at a considerable level. As a consequence, the number of policies and the level of assets under management grew year on year whereas the underlying risk profile of the Company remained substantially unchanged. No significant business or other events occurred having a material impact on the solvency and financial condition of the undertaking. Furthermore, due to no significant alteration of the business proposition and the features of Company's products, together with the above mentioned business growth, the Solvency position over the year strengthened, with the Solvency II ratio increasing from 221% at 31st December 2016 to 234% at 31st December 2017. The amount of SCR as of the end 2017 is equal to €109 million and the eligible amount of the eligible own funds to cover the SCR is equal to €254.4 million, consisting of all Tier 1 asset: €0.65 million as Ordinary Share Capital, €9.35 million as capital contribution, approved by the Central Bank of Ireland as own fund Tier 1 and €244.4 as reconciliation reserve. Same own funds are eligible to meet MCR, which amounts to €45.5 million.

The below table reports the main indicators for the underwriting performance of the Company.

€/000	31/12/2016	31/12/2017	YE2017 vs YE2016
Premiums Earned	€ 1,623,414	€ 1,525,923	-6%
<i>of which classified as premiums within FS</i>	€ 3,533	€ 5,776	+63%
Claims and benefit incurred	€ 911,027	€ 1,243,961	+37%
<i>Of which classified as claims within FS</i>	€ 134,480	€ 172,965	+29%
Unit Linked Fund at the beginning of the year	€ 5,658,317	€ 6,446,059	+14%
Unit Linked Fund at the end of the year	€ 6,446,059	€ 6,700,283	+4%

Detailed below the composition of the premium earned by product:

€/1000	2017
Pleiadi	13,208
Star	30,136
AZ Style	551,204
AZ Infinity Life	138,043
AZ Navigator & Plus	793,332
	1,525,923

As mentioned above, the distribution into the Italian market is carried by a single distributor, hence all the premium refers to its activity.

The Company is required to hold sufficient assets to match the policyholders liabilities at all times and the Board has the primary responsibility to ensure the Company has the adequate level of capital to cover its solvency needs, in relation to the nature and the scale of the business, and to fulfil any liquidity obligation in the short to medium term.

The Company's financial year end is 31st December each year and it reports its results in Euro.

The Company is classified as a Medium High Risk firm under the Central Bank of Ireland (“CBI”)’s risk-based framework for the supervision of regulated firms, known as PRISM or Probability Risk and Impact System. The Company is subject, in relation to its governance, to the provisions of the Companies Act of 2014 and the CBI’s Corporate Governance Requirements for Insurance Undertakings of 2015.

The Board and Relevant Officers have primary responsibility for ensuring that the Company is suitably managed and directed. Accordingly, it is of paramount importance that the Directors and Relevant Officers of AZ Life have integrity and are suitable, as these individuals can have significant and direct impact on the safety, soundness and reputation of the Company and the Azimut Group (the “Group”) of which the Company is part.

The Company has established a ‘Fit and Proper’ policy to ensure that existing and new Directors and Relevant Officers of the Company are fit and proper: appropriate for the position to which they may be appointed and continue to be fit and proper while they hold their position.

The Board of Directors of the Company retain ultimate responsibility for the oversight of the business and the definition of the Company’s general strategies and risk appetite. The implementation of the strategy is mandated to the executive management in Dublin.

The Board has established four committees:

- Audit Committee;
- Risk and Compliance Committee;
- Products Committee;
- Investment Committee.

In addition to the committees, the Company has established a periodical Senior Management Governance Forum (“SMGF”), with the idea that this should represent the venue and occasion for

sharing information and for discussing aspects including relevant risk issues across the 3 lines of defence.

During 2017, the Company has implemented significant steps in relation to its governance structure, including changes in the Chairperson, among the two Independent Non-Executive Directors (“INEDs”), and in the Committee structures. It also took place successfully the migration project for the change of the Policy Administrator provider without affecting the business model of the Company, which is relying on third party provider also for important and critical activities. The effective date of the migration was 1st January 2018.

AZ Life focuses on increasing income by increasing the net assets under management. This is achieved by generating new business whilst reducing lapses.

The Company does not aim to take on any liquidity risk and so maintains appropriate capital to cover this. However, the Italian tax prepayment combined with high sales of a specific product have the potential to threaten liquidity.

This combination of factors could impact on the Company’s liquidity due to the expected liquidity issues, even if the level of profits is significant. The management has defined a strategy to mitigate the liquidity risk the Company may face and monitors the new business mix on a regular basis.

Other key risk faced by the Company are:

- Higher than expected lapses, leading to reduction both on the immediate annual income and the capitalised value of projected future income;
- Adverse market impacts, leading to a fall on the Assets Under Management and to a reduction on both immediate income and the capitalised value of the projected future income stream.

A. BUSINESS AND PERFORMANCE

A.1 Business and external environment

AZ Life dac is a Regulated unit-linked life assurance private company limited by shares. The Company’s registered office is: 2nd Floor, Block E, Iveagh Court, Harcourt Road, Dublin, D02 YT22, Ireland.

The Central Bank of Ireland (“CBI”) is responsible for the financial supervision of the Company, whose address is: PO Box 559, New Wapping Street, North Wall Quay, Dublin 1, Ireland.


The Company's external auditor is PricewaterhouseCoopers, Chartered Accountants and Statutory Audit Firm, One Spencer Dock, North Wall Quay, Dublin 1, Ireland.

The Company is wholly owned by Azimut Holding S.p.A. (“Azimut Holding”), an Italian holding company, listed on Milan Stock Exchange and ranked amongst the first 40 companies of the index. Azimut Group is the largest independent asset management Group in Italy since 1989 with a presence in 17 countries all over the world.

The Company is authorized to carry on Class I and III business under the Solvency II Directive, however, currently all policies issued by the Company so far are classified as “Life insurance obligations –Index-linked and unit-linked insurance “ (line of business D(31) as per the SII Directive), through cross-border activity into Italian market. From 2018, policy administration services are outsourced to Previnet, an insurance services provider established in Italy.

No significant events occurred during the reporting period.

The shareholder, Azimut Holding, has the entire stake of the Company and 100% of the voting right as presented in the organisational chart below.



A.2 Performance from underwriting activities

The Company's portfolio was issued in Italy to Italian resident policyholders with very few with fiscal residence outside Italy.

As the business traded by the Company is related to Unit Linked insurance policies the underwriting risk is very limited.

The overall amount of the premiums is reported within the audited Financial Statements of the Company, prepared in accordance with the International Financial Reporting Standards (IFRS), based on the following rules: for the investment contracts, premiums and claims are not reflected in the statement of comprehensive income as written premiums, claims and benefit incurred, but rather are reflected in the Statement of Financial Position in the financial assets and liabilities in accordance with IAS 39; insurance contracts, premiums and claims are disclosed separately within the Financial Statements.

As the Company is marketing their products within Italian market with one line of business only (Unit Linked policies), the following figures are related to the entire Company.

€/000	31/12/2016	31/12/2017	YE2017 vs YE2016
Premiums Earned	€ 1,622,41	€ 1,525,923	-6%
<i>of which classified as premiums within FS</i>	€ 3,533	€ 5,776	+63%
Claims and benefit incurred	€ 911,027	€ 1,243,961	+37%
<i>Of which classified as claims within FS</i>	€ 134,480	€ 172,965	+29%
Unit Linked Fund at the beginning of the year	€ 5,658,317	€ 6,446,059	+14%
Unit Linked Fund at the end of the year	€ 6,446,059	€ 6,700,283	+4%

The amount of premiums earned in 2017 is slightly below the level of the previous year, confirming the expected underwriting performance and the considerable high level of selling activity carried on by the distributor.

The increase of the amount of Claims and benefit incurred has been in particular heavily impacted by a one-off event related to the product AZ Navigator Plus, which caused a significant amount of surrenders during 2017.

A.3 Performance from investment activities

In consideration of the nature of the products sold by the Company, no investment risk is taken by the Company on behalf of policyholders or shareholders. The policyholders bear the investment risk in relation to linked assets and the Company's role is to manage policyholder assets in accordance with the investment policies established for each internal funds. Shareholder own funds assets are invested in cash, Government Bonds and monetary mutual funds with an aim to have high liquidity and to preserve the capital position of the Company. The return of such assets are reported as Investment Income within the Statement of Comprehensive Income while the effect deriving from the fair value valuation at each year end is reported as Other Comprehensive Income and recognised in equity. In 2017 the overall investment income of the Company is not material, being equal to about €15 k (last year it was equal to €29 k).

AZ Life does not hold any investments in securitisations.

A.4 Performance of other activities

AZ Life's only activity is to carry on unit-linked business as reported within the section A.2

As a consequence the Company derives its source of income as fees and commission from the unit-linked internal funds, which are netted of any fees to be paid to the distributor.

€/000	31/12/2016	31/12/2017
Fees earned	€ 94,457	€ 110,950
Fees paid	€ 63,668	€ 72,649

The increase of the fees earned, and the corresponding amount paid to the distributor, was driven by the increase of the average asset under management in 2017. The main driver of such growth is the net collection realized during the year.

€/000	31/12/2016	31/12/2017
Administration Expenses	€ 7,683	€ 8,629

As far as the administration expenses are concerned, the actual figure for 2017 is higher of about €1 million compared to last year, as a consequence of the migration project from the former Policy Administration outsourcer (DST – formerly IFDS Percana) to Previnet.

A.5 Any other information

No other information to be provided.

B. SYSTEM OF GOVERNANCE

B.1 General Information on the System of Governance

B.1.1 Overview

The Company is classified as a Medium High Risk firm under the Central Bank of Ireland (“CBI”)’s risk-based framework for the supervision of regulated firms, known as PRISM or Probability Risk and Impact System. The Company is subject, in relation to its governance, to the provisions of the Companies Act of 2014 and the CBI’s Corporate Governance Requirements for Insurance Undertakings of 2015.

The Board of Directors of the Company retain ultimate responsibility for the oversight of the business and the definition of the Company’s general strategies and risk appetite. The implementation of the strategy is mandated to the executive management in Dublin.

B.1.1.1 Board of Directors

As of 31.12.2017, the Board of the Company was comprised of nine directors, among whom three executive (PCF 1) and six non-executive (PCF 2), including two Independent Non-Executive Directors (“INED’s”). Meetings are validly held and resolutions passed with a majority of the members of the Board.

The Board of AZ Life, as of 31.12.2017, comprised of:

1. Marita Freddi – Chairperson (PCF 2 and PCF 3)
2. Davide Cesaro – General Manager (PCF 1 and PCF 8)
3. Filippo Fontana – Chief Financial Officer (PCF 1 and PCF 11)
4. Giacomo Mandarino – Chief Risk Officer (PCF 1 and PCF 14)
5. Sergio Albarelli (PCF2)
6. Paul Dalton - Chair of Audit Committee (INED, PCF 2 and PCF 4)
7. Clive Kelly - Chair of Risk and Compliance Committee (INED, PCF 2 and PCF 5)
8. Claudio Basso - (PCF 2)
9. Joao Gomes Sequeira – (PCF 2)

B.1.1.2 Company Secretary

Matsack Trust Ltd., with registered office in 70 Sir John Rogerson's Quay, Dublin 2, Ireland.

B.1.1.3 Committees

During 2017, the Board has introduced the Product Committee and the Investment Committee and revised the Audit / Compliance Committee and the Risk Management Committee. These changes are also related to the governance structure changes mentioned in the Summary.

Starting from 2018, the committee composition will be:

- Audit Committee;
- Risk and Compliance Committee, with two separate sessions covering Risk and Compliance topics respectively;
- Products Committee; and
- Investment Committee.

The Chairman of each Committee systematically reports to the Board on any matters discussed by the respective Committee, thus ensuring adequate visibility of any relevant issues by all Directors.

Audit Committee

The Audit Committee ("A Committee") is made up of three non-executive directors, the majority of whom being independent, in accordance with the provisions of the Corporate Governance Code for Credit Institutions and Insurance Undertakings. It resolves with a majority of votes. The Chairman of the A Committee is an INED of the Company, Mr. Paul Dalton. The composition of the A Committee is as follows:

Paul Dalton (Chairman)

Clive Kelly (Member)

Joao Gomes Sequeira (Member)

The A Committee is governed by specific Board approved terms of reference ("TOR") that regulate the functioning and competences of the A Committee, ensuring its independence. For instance, the A Committee is granted reasonable and adequate resources to seek expert professional advice where required in order for the Committee to discharge its responsibilities.

The A&C Committee has the following main competences:

- 1) Monitors the effectiveness and adequacy of the company's internal control, internal audit and IT systems;
- 2) Monitor the financial reporting process and submit recommendations and proposal ad appropriate;
- 3) Liaises with the external and internal auditor particularly in relation to their audit findings;
- 4) Reviews the integrity of the Company's financial statements and ensuring that they give a "true and fair view" of the Company's financial status;
- 5) Reviews any financial announcements and reports and recommends to the Board whether to approve the institution's annual accounts;
- 6) Assesses the auditors' independence and the effectiveness of the audit process.

The A Committee assists therefore the Board in discharging its responsibilities for:

- The integrity and reliability of the Company’s financial statements;
- The effectiveness of the Company’s audit activities, in the framework of the Company’s overall risk management system;
- The monitoring of effectiveness, independence and objectivity of the external auditors and the other subjects involved in the audit functions of the Company.

Risk and Compliance Committee

The composition of the Risk and Compliance Committee (“R&CC”) is as follows:

1. Mr. Clive Kelly (Chairman)
2. Mr. Paul Dalton (Member)
3. Mr. Giacomo Mandarino (Member)
4. Mr. Davide Cesaro (Member)
5. Mr. Joao Gomes Sequeira

The Chairman of the R&CC is the other INED of the Company, Mr. Clive Kelly.

The R&CC is also governed by specific terms of reference (“TOR”) that regulate its functioning and competences, ensuring its independence.

In relation to Compliance, the R&C Committee has the following main competences:

- 1) Reviews the framework established by the Company for monitoring compliance with laws and regulations and the results of management investigations for any non-compliance;
- 2) Periodically considers the duties and responsibilities of the Compliance Function and evaluates its role in confirming that regulatory and legal obligations are being met;
- 3) Ensures that a regular compliance update is produced and reviewed by the Compliance Officer of the Company, reporting any material issues, which may for example, negatively affect the Company’s reputation, to the Board; and
- 4) Ensures that reasonable and adequate resources are made available to the function.

In relation to Risk, the R&CC is responsible for the following:

- a) Overseeing and providing advice to the Board on the risk exposures of the Company and future risk strategy.
- b) Advise the Board on risk appetite and tolerance for future strategy, taking account of the Board’s overall risk appetite, the financial position of the Company and, drawing on the work of the A&C Committee, the External Auditor, the Head of Actuarial or any outsourced key service provider and the capacity of the Company to manage and control risks within the agreed strategy.
- c) Oversee the Risk Management Function.
- d) Ensuring the development and on-going maintenance of an effective Risk Management System within the Company effective and proportionate to the nature, scale and complexity of the risks inherent in the business.
- e) Advising the Board on the effectiveness of strategies and policies with respect to maintaining, on an ongoing basis, amounts, types and distribution of both internal capital and own funds adequate to cover the risks of the institution.

The R&CC assists therefore the Board in:

- a) the monitoring and assessment of effectiveness of the Company's Risk Function, in the framework of the Company's overall Risk Management System;
- b) The monitoring of effectiveness, independence and objectivity of the Risk and Compliance Function and of any other subject, internal or external (Head of Actuarial, auditors) involved in the assessment of the Risk and Compliance function of the Company, the Company's Risk profile and/or its overall Risk Management System.
- c) The implementation of the Company's risk strategy and maintenance thereof.
- d) The oversight of any issues having a potential impact on the risk and/or compliance profile of the Company.

Products Committee

In 2017 the Company established the Products Committee, under the authority of the Board, with responsibilities to discuss and analyse any of the following matters:

1. General Product offer of the Company, range of products and possible changes, enhancements or improvements;
2. Analysis of characteristics and performances of products, including without limitation, in case of changes, pricing review, in accordance with the applicable Investment Policy of the internal funds; and
3. Possible amendments, whether required by changing market or regulatory conditions, or due to requests. Where the amendment is considered material, subject to the prior discussion at the Board. For this purpose:

Material is any amendment that can negatively impact on profit/profitability and/or on the future liquidity or capital position of the Company in a significant manner. For this purpose, significant is an impact that would be considered such by a reasonable person, in a sound and prudent management perspective. The Company will consider material any new products that are not similar by nature and characteristics to existing or previous products (e.g. in terms of profitability, nature of product and applicable rules).

The Product Committee is expected to cover the key areas of the new products assessment and oversight, including the identification of the target markets and the process in place to assess the clients are fairly treated, being the members expected to be able to contribute actively to any discussion or assessment based on expertise in any of the following areas:

- a. Risk / Actuarial
- b. Legal, with regard to the legal / regulatory framework of any involved jurisdiction;
- c. Finance and Accounting.
- d. Portfolio Management and asset allocation.
- e. Marketing and Operations.

In addition, where considered appropriate by the Chairman or any other members, the Committee is authorised to obtain external professional advice and to secure attendance of anyone it considers having the required expertise in specific technical matters related to the creation / monitoring of products or to any of the other matters for which the Committee is competent.

Investment Committee

In 2017 the Company established the Products Committee, under the authority of the Board, with responsibilities to discuss and analyse any of the following matters:

1. Economic scenarios, threats and opportunities of investment.
2. Current and envisaged portfolio allocation, consideration of possible changes.
3. Performance analysis.
4. Oversight of activities including unit pricing operations.

The members should be able to contribute actively to any discussion or assessment based on expertise in any of the following areas:

- a. Portfolio Management and asset allocation.
- b. Economic and financial analysis
- c. Risk
- d. Products (of the Company, the Group or third parties).

The current members of the committee are as follows:

- a. Chief Investment Officer (Chair)
- b. CEO (Member)
- c. CRO (Member)
- d. One non-executive director (Member)

Control Functions

The Company has established the four independent key control functions as per the Solvency II regime and the Corporate Governance Code Requirements :

1. Risk Management
2. Compliance
3. Actuarial
4. Internal Audit

Individuals with specific competences are in charge of these functions within the Company (Risk Management and Compliance) or the Group (Head Internal Audit, a member of the Holding Risk function), whereas the Actuarial function is outsourced and entrusted to Mr. Michael Culligan (Milliman Ireland), being the Head of Actuarial Function (PCF 48).

Chief Risk Officer (“CRO”, PCF 14)

The role of CRO is mandated to Mr. Giacomo Mandarino who is also an executive Director and a member of the Risk & Compliance Committee and Products Committee, thus ensuring direct reporting and interaction at Committee and Board level on risk related matters.

The main responsibilities of the CRO include:

1. The oversight of the Company’s Risk Management Framework;
2. Monitoring risks and regularly reporting thereon to the Risk Committee and/or the Board, as relevant; and

3. Liaising with all relevant parties (Head of Actuarial Function, General Manager, Chief Financial Officer, Head of Compliance) ensuring, among other things, that the annual Own Risk Solvency Assessment (“ORSA”) is prepared and updated as required and submitted to the Board for consideration and, if thought fit, approval.

Head of Compliance – AML Responsibilities (PCF 15)

The Company has appointed Ms. Esther Fernandez Espina as dedicated Head of Compliance with AML Responsibilities (PCF 15). The Head of Compliance reports to the R&C Committee and the Board and is responsible for the implementation and oversight of the general compliance plan and compliance strategy of the Company.

The responsibilities of the Head of Compliance include:

1. Monitoring compliance within the company and its outsourced service providers, making recommendations where required;
2. Reporting on significant instances of non-compliance to the R&C Committee and/or the Board
3. Monitor any changes affecting compliance and any regulatory changes and inform the Company and/or its outsourced service providers as relevant, where such changes have implications for the Company’s processes.
4. Assisting in any correspondence with the CBI and any other Authority.

The R&C Committee and the Board oversee the [risk based] compliance plan and the outcomes thereof.

The Company draws upon external Compliance and Risk support services as needed.

Head of Actuarial Function (PCF 48, Outsourced)

The Head of Actuarial Function (“HoAF”) is outsourced to Mr. Michael Culligan, partner of Milliman (Ireland).

Head of Internal Audit (PCF 13, Outsourced)

The Head of Internal Audit Function is outsourced to the manager of the Group Internal Audit (Mr. Roberto Bolgiani). In this task, the Head of Internal Audit is supported by a team of Deloitte (Milan).

The Internal Audit Function provides an independent and objective service for the auditing of any relevant areas of activity.

B.1.2 Main Changes in Governance Structure

During the year the Company implemented various measures to enhance its overall governance structures, following years of rapid and significant growth:

1. performing a Board Effectiveness Review to ensure the Board is acting effectively and to identify potential areas of improvement, leading to the redefinition of Terms of Reference for the Board, the replacement of the Audit/Compliance Committee and Risk Committee with the Audit Committee, Risk and Compliance Committee, and the introduction of the Products Committee;
2. Reviewing the composition of the Board, including the appointment of a new Chairperson and two new INEDs, being the former ones reached the nine years of engagement; and
3. Reinforcing the risk management function with an additional resource to support the CRO in risk and actuarial matters, allowing for proper backup and succession.

B.1.3 Remuneration Policy and Practices

The Company remunerates its resources based on the skills and experience, on one hand, and the dedication and results, on the other hand, as well as based more in general on the overall contribution brought to the Company and its business.

For this purpose, it is normally provided that each employee receives a fixed salary and, to a smaller extent, a variable remuneration, depending on the results obtained in areas such as:

1. General conduct;
2. Sense of responsibility and capability to understand and solve problems;
3. Competence shown and work completed, for the overall enhancement of the area of respective expertise ;
4. Interaction with other employees ; and
5. Improvements brought to the Company

The Company provides a range of benefits to employees, including contractual salary, paid holidays and other variable arrangements for the provision of benefits such as health insurance, accommodation expenses contribution or education-related contributions.

The Company encourages the adherence of employees to supplementary pension or early retirement schemes, for instance accepting, in specific cases, to contribute to any payments into such schemes in a specific proportion and up to a certain amount.

The Company does not follow any policy or practices that could encourage “short termism” or excessive risk taking. For instance, most managers are shareholder of the holding company of the Group (Azimut Holding) and bound by a long term shareholders’ agreement, which encourages a process of decision making oriented to long-term as opposed to short-term goals, ensuring more attention is dedicated to sound and prudent management in a long-term perspective. As a consequence, no manager (or employee) in the Company would feel pushed to inflate results or obliged to increase performance every year, even though the Company has effectively experienced significant growth year on year, in terms of both Assets Under Management and revenues, since 2009.

The Remuneration Policy is applied and administered under the supervision and responsibility of the Chairperson of the Company.

B.1.4 Material Transactions

There were no material transactions with the Shareholder, with persons who exercise a significant influence on the undertaking and / or with members of the administrative, management or supervisory bodies in the Company.

The integration of the Risk Management, Internal Audit and Compliance functions into the organisational structure and the decision making process of the Company is reported within the section B4.

B.2 ‘Fit and Proper’ Requirements

The Company has adopted a Fitness and Probity Policy, which sets out the due diligence checks that must be carried out for any PCF or CF holder or applicant.

For this purpose, any candidate PCF or CF needs to comply with the standards required under the Fitness and Probity Regime introduced with the Central Bank Reform Act of 2010, and any successive integration, modification or implementation.

In particular, any PCF or CF holder or applicant needs to have the necessary skills, experience and qualifications appropriate to their position in accordance with the CBI Guidelines and CBI's guidance on Fitness and Probity Standards of 2014.

Areas that are to be considered for this purpose include:

- Financial Soundness;
- Honesty, Integrity and reputation; and
- Competence and Capability.

This is further implemented through the following:

- Identification;
- Compliance with the minimum competency requirements;
- Professional Qualifications;
- Continuous Professional Development ;
- Interview and application ;
- References ;
- Records of previous experience;
- Concurrent Responsibilities; and
- Individual Questionnaire and candidates declaration (e.g. engagement letter).

For PCFs, further scrutiny is given to the following aspects:

- Experience, including at Board level
- Capability to understand the business in all its aspects
- Capability to see and manage risks for the organization
- Expertise and expected specific contribution to the Company or its Board (e.g. specific skills in actuarial, legal, commercial or financial matters)

The appointment of a PCF holder is further conditional upon the CBI's approval and, additionally, on a yearly basis all PCF's (and CF) holders are requested to confirm they still have the requirements of fitness and probity requirements. Further, on a yearly basis the PCF holders are subject to specific assessment e.g. through the Board Performance review, that is conducted both on the Board as a collective body and on the individuals. In that regard, the Board has performed a more holistic Board effectiveness review during 2017, leading to, among other things, changes on the Board composition

B.3 RISK MANAGEMENT SYSTEM

The Company has implemented a Risk Management Policy that acts as a guideline for the Company's approach to Risk Management. The Company operates a simplistic operating environment with close collaboration between all involved in the activities of the Company. Such a close risk environment enables the identification of risks early and therefore risks are addressed in a timely manner.

The risk landscape considers the key risk categories according to the Solvency II Directive, those in respect of life assurance and those specific to the Company's risk profile and its business model. The Risk Management Function closely collaborates with the Compliance Function to monitor the legal, regulatory and supervisory environment to determine, together, the identification of any new risks.

Risk Management System (the “RMS”) is underpinned by the core risk management policies according to the requirements of the Solvency II Directive, namely, but not limited to: underwriting and reserving, asset-liability management, investment, liquidity and concentration, operational and reinsurance and other risk mitigation techniques. The policies are reviewed, and revised if necessary, on a periodic basis by the Board.

A core element of the RMS is the Board approved Risk Appetite Statement (the “RAS”). The RAS is reviewed no less than annually and is periodically examined in such instances as the regular ORSA Report, also part of the RMS. Together these elements ensure that the Company has a regular and thorough approach to monitoring the status of the Company’s risk related matters.

The RMS is integrated into the organisational structure and in the decision making processes of the Company with proper consideration of the persons who effectively run the undertaking or whom hold key functions.

The RMS includes the following:

- strategic decisions set by the Board and policies on risk management;
- definition of the Company’s risk appetite and overall risk tolerance limits; and
- identification, measurement, management, monitoring and reporting of risks.

The Company’s Risk Management Framework (the “RMF”) enables the Board and management to understand and appropriately manage and mitigate the risks associated with the Company’s objectives over the short, medium and long term, together with the overall level of risk embedded within the function and operational processes and activities, including those which are the subject of outsourcing arrangements, of the Company.

The RMF is intended to reduce, but cannot eliminate the range of possibilities, which might cause detriment to the Company. Similarly the RMF cannot provide protection with certainty against any failure of the Company to meet its business objectives, or guard against material errors, losses, fraud or breaches of laws and regulations.

Taking all of these factors into account the RMF is intended to provide reasonable assurance that the Company will conduct its business in an orderly and legitimate manner on a continuing basis and that reasonably foreseeable circumstances will not prevent, or limit, the Company from achieving its business objectives.

The business strategy of the Company is to provide life assurance products on a freedom of establishment basis, primarily in the Italian market. The risk strategy of the Company is to provide low capital intense, low risk products with sustainable profitability. Investment risk is borne by policyholders and not by the Company, as emphasized by its “No Guarantee Principle”. The Company limits investment risk on its own funds.

The Risk Management Function monitors risks faced by the Company on a continuous basis. This includes emerged and emerging risks. The risk identification exercise is carried out on a no less than annual basis.

The risk identification process broadly follows the below steps:

- identify and list all the risks for which the Company is exposed to;
- filter the list of risks to those which are quantifiable; and
- from the list of quantifiable risks, assess the materiality of these risks, based on quantitative and qualitative criteria

The risk identification process involves all the senior management of the Company. In particular:

- the CRO is responsible for identifying the risks facing the Company ;
- the CRO reports these risks to the senior management (CEO and CFO and Operations Manager) who ensure that all of the risks are identified; and
- the CRO quantifies the risks after consulting with the other senior management and ensures consistency with the risk appetite of the Company.

The risks are defined and quantified in a Risk Register and presented to the Risk Management Committee (RMC) with key risks reported by the Chair of the Committee to the Board of Directors, who, after due care and attention and challenge, approve the document.

The CRO (and other senior management) monitor existing and new risks to the business on an ongoing basis. The Risk Register is updated as a result of this ongoing monitoring and presented for approval at the next Risk Committee and Board of Directors meetings.

The RMC receives regular reporting from the CRO. No less than annually the CRO presents a fuller risk report in relation to the outcome of the annual risk assessments undertaken, in line with the RMF, including the outputs of the annual statutory financial statements and regulatory reporting.

The Board sets the overall business strategy of the Company and the CRO sets the Risk Strategy of the Company, as approved by the Board. The Risk Management Function is one of the four key control functions maintained by the Company and is an integral part of the Company's "three lines of defense".

The CRO is responsible for the implementation of the RMS. The Risk Management Function has sufficient resources and authority to discharge its duties. During the year, an additional resource reinforced the risk management function to support the CRO in risk and actuarial matters, allowing for proper backup and succession. The CRO promotes a culture of risk awareness and reporting throughout the Company and its operations.

The Company adapts to new product development as demanded from its distribution networks and policyholders. Risk Management is an integral part of any new product development. In particular the evaluation of product pricing and the associated risks, including operating within the Company's risk appetite, tolerance and limits, and the assessment of own funds and solvency margin required to support same. The Risk Management Function is an integral part the Products Committee that operates within agreed boundaries set by the Board.

The RMS is integrated in to Board level decision making whereby the CRO, in addition to being a member of the Risk and Compliance Committee, is also an active Board Member. Such arrangement ensures that Risk is well represented within the Board and hence decision making level.

The Board of directors is ultimately responsible for ensuring the effectiveness of the risk management system, setting the undertaking's risk appetite and overall risk tolerance limits as well as approving the main risk management strategies and policies.

The Board should ensure that such strategic decisions and policies are commensurate with the Company's nature, scale and complexity and any specificities as required by its Group. The Board ensures that the specific operations, which are material, and associated risks of the Company are covered and that an integrated, consistent and efficient risk management framework is put in place.

The Board has established a Risk and Compliance Committee that adopts Board approved terms of reference. The primary role of the R&CC, with regard to risk, is to advise the Board on risk appetite and tolerance for future strategy, taking in to account of the Board's overall risk appetite, the current financial position of the Company, and, drawing on the work of the Audit Committee, the external

Auditor and the internal requirements of the Group, the capacity of the Company to manage and control risks within the agreed strategy. The R&CC oversees the effectiveness of the RMF, which is managed on a day to day basis by the CRO. The R&CC advises the Board on the effectiveness of strategies and policies with respect to maintaining, on an ongoing basis, amounts, types and distribution of both internal capital and own funds adequate to cover the risks of the Company.

The CRO's primary responsibility is to report to the Board on risk themes. The CRO reports to the Board periodically with direct access to the Chair of the Board. The CRO promotes a risk culture within the Company that fosters close collaboration between business functions.

B.4 ORSA

The Company maintains a Board approved Own Risk Solvency Assessment Policy (the "ORSA", the "ORSA Policy"). The ORSA is a dynamic forward-looking process. Stress and scenario testing, as pre-determined by the Board in advance, is an integral and important component used in the Company's determination of its own capital needs as it sets and evaluates the adequacy of its internal targets and operating capital and liquidity level throughout the business planning cycle.

The ORSA serves as a tool to enhance the Company's understanding of the interrelationships between the business strategy, its risk profile and capital and liquidity needs. The ORSA considers all reasonably foreseeable and relevant material risks, is forward-looking and consistent with the Company's business and strategic planning. The ORSA also allows the Company to test its resilience under different scenarios, that are approved by the Board after a thorough discussion.

The ORSA process enables the Company to review its strategy and amend its future business plans due to unforeseen changes in any of the following: underwriting, business mix, pricing of reinsurance, an increase or decrease in investment returns, concentration of risks or return of capital, to name a few.

The Board, as ultimate owners of the ORSA, set and subsequently challenge the assumptions and the output. In particular the Board verifies:

- the risk profile of the Company and the key drivers of the risk profile are in line, over the near future, with the approved risk appetite and tolerance limits;
- whether there is sufficient available capital and liquidity to support the current business plan and if the target capital and liquidity requirement are met;
- if there are risks that should be monitored more frequently;
- any material changes to the risk profile in the short/medium term;
- risks not covered in the regulatory Solvency Capital, such as, but not limited to: reputation, strategic, governance, etc..;
- key sensitivities in the Company's Balance Sheet, notably its liquidity position, and in the Solvency Capital requirements; and
- key drivers of expected profits.

The Company has entrusted the CRO to be responsible for coordinating the overall ORSA process.

The CRO is the responsible for the governance of the processes and procedures in place to conduct the ORSA and will contribute to the ORSA by assessing the risks currently faced by the Company including short or long-term risk. The CRO will ensure the consistency between risk profile, approved risk tolerance limits and the overall solvency needs.

The starting date of ORSA process, which takes place at least annually, is aligned with the business planning cycle. A non-regular ORSA may be triggered by internal or external events, such as, but not

limited to: acquisition of another business, a market driven event, change in business mix and/or product offering, changes in risk profile or change in capital needs (i.e. an increase in capital).

An ORSA Report is prepared according to the minimum set of contents and requirements prescribed by the ORSA Policy and regulatory guidelines. The Compliance Function submits the ORSA Report, after the Board approval, to the Company's Supervisory Team at the Central Bank of Ireland, as accompanied by the due Director certification within the timeframes prescribed.

The Head of Actuarial Function provides an actuarial opinion on the ORSA. The opinion addresses the following areas:

- The range of risks and the adequacy of stress scenarios considered as part of the ORSA process;
- The appropriateness of the financial projections included within the ORSA process; and
- Whether the undertaking is continuously complying with the requirements regarding the calculation of Technical Provisions and potential risks arising from the uncertainties connected to this calculation.

The CRO presents the findings of the ORSA Report to the Company's staff members, increasing the awareness of the inter-connectedness of operational activities to the overall ORSA Process.

The Company's Internal Audit Function periodically reviews the ORSA Process with any improvements recommended therein.

The Company adopts the Standard Model with respect to calculating its Solvency Capital Requirements (the "SCR") in accordance with conditions required of a life assurance Company under the Solvency II directive. Own funds are managed in accordance with the Board approved Capital Management Policy.

The outputs of the SCR by key risk categories are assessed against the risk appetite, tolerance and limits set by the CRO as approved by the Board in the context of the overall RMS. Any risk areas that fall outside of certain limits set within the RAS are identified and reported upon to the relevant authority levels set with the RAS (i.e. to the Risk Management Committee, Board and Central Bank of Ireland as appropriate).

No less than annually the Company performs, as part of its annual statutory financial statements and regulatory return, a full calculation of its technical provisions and Solvency needs, as determined by the Head of Actuarial Function and the supporting actuarial team. On a quarterly basis, as part of the Company's regular regulatory reporting, the Company monitors the solvency margin. In addition, the CRO regularly reports to the R&CC and Board on items that, through the ORSA Process, have been identified as items that 'might' have an adverse impact on the Company's Solvency Margin, such items include, but are not limited to: product mix and the impact to liquidity and profitability, and the Italian tax prepayment asset held by the Company.

The ORSA Process enables the Company to project and determine future capital and liquidity needs in order to sufficiently support decision making.

The CRO is an active Board member. The Head of Actuarial Function attends regularly Risk Committee Meetings. This ensures that Risk is represented at the highest decision making authority of the Company.

B.5 Internal Control System

The Company operates on an Internal Control System hinging on 3 lines of defence.

In this model, a first level of control lies with the management, with a duty to own and manage activities and controls on the correct conduction of the same (management controls and internal control measures). In this sense, the management have responsibility for directly assessing, controlling and mitigating risk.

A second line of defence is represented by certain control functions, namely Compliance, Risk and Actuarial Function.

A third line of defence is represented by the Internal Audit, which through a risk based approach provides independent review, and therefore reassurance or suggestions for improvement, in relation to the activities and control measures implemented by the other functions, detecting possible weaknesses and reporting directly to the Audit Committee and/or the Board.

B.6 Internal Audit Function

The Head of Internal Audit Function is outsourced to the manager of the Group Internal Audit (Mr. Roberto Bolgiani). In this task, the Head of Internal Audit is supported by a team of Deloitte (Milan).

Audits are conducted based on an Internal Audit plan approved by the Board every year and the Internal Audit activities conducted, as well as their progression are reported directly to the A Committee, at least on a quarterly basis. The Audit Committee oversees therefore the Audit Plan, its implementation and any outcomes thereof.

The Board has appointed the CFO as internal referent for the Internal Audit activities (currently, Mr. Filippo Fontana), who is answerable to the Internal Audit for all the local coordination and therefore oversees the collection and timely submission of all required materials to the Internal Audit Function.

Internal Audit reports highlight any significant control failings or weaknesses identified, and in the latter case any remedial actions and timings agreed with the management of the Company. In this sense, any findings are shared with the management that must respond to those findings and recommendations. Matters that cannot be resolved through normal channels can be escalated to the Committees and the Board of Directors.

The Internal Audit function has direct access to:

- the day-to-day operations of the business and any functions, staff, documents and service providers of the Company; and
- the Audit Committee and the Board, which approves the Internal Audit Plan and is thereafter competent to hear on any progress thereon

The above described Internal Audit System ensures therefore full independence of the Internal Audit from the management and/or from the day-to-day operations of the business.

B.7 Risk culture

The Board of Directors and Risk Management Function promotes a positive and open risk management culture within AZ Life. AZ Life employees are encouraged and required to report and log operational

risk events, breaches, systems and control failures, etc. and to escalate events to their line manager, so that they can be examined and addressed appropriately.

A strong risk culture is further embedded within AZ Life through the following:

- The CRO is a member of the Board of Directors allowing him to promptly escalate any potential issue he is aware of and to take part to any strategic decision;
- The CRO is a member of the products committee, supporting the fair treatment of customers and identifying any potential changes in AZ Life's risk profile in case of changes in the product offering ;
- The CRO is involved in the material initiatives which may impact on the risk profile of the Company; and
- The CRO works closely with the senior management for the assessment and the review of the risks faced by the Company.

B.8 Compliance Function

The Head of Compliance is a member of the Risk and Compliance Committee and regularly attends the Board meeting to report to any compliance matter.

Furthermore, the Compliance function:

- a) Establishes the controls and assurance tests required to ensure the compliance with the relevant rules at all times (identification). In case of findings / or omissions that represent a compliance breach, this is recorded in the compliance breach log and reported accordingly in the compliance report for the Risk/Compliance Committee and the Board.
- b) Interacts with the staff, the top management and the Risk Committee. The Compliance (as well as Risk) Function reports directly to the Committees and the Board, independently from the executive management. The reporting activities take place in accordance with the Compliance Policy and other policies that protect the independence of function.

B.9 Actuarial Function

The Head of Actuarial Function ("HoAF") is outsourced to Mr. Michael Culligan (Milliman Ireland) . The Company is also supported by a dedicated actuarial team at Milliman. The outsourcing of this arrangement adds independent oversight of the Company's Actuarial Function, and the possibility for the Company to obtain the level of resources required by any contingencies and or requirements as they may arise.

Internally, the HoAF is supported by Mr. Giacomo Mandarino (PCF1 and PCF 14), in consideration of his background as an actuary and of his long time experience in actuarial and risk matters.

The responsibilities of the HoAF include, but are not limited to, the following:

1. Review and validate the calculation of the technical provisions for the Company, including:
 - ensuring appropriate methodologies, assumptions and models are adopted, discussed and understood by the Board;

- assessing the quality and adequacy of data used, in particular, without limitation, to assess the consistency of internal and external data used in the calculation of technical provisions against the data quality standards as set in Solvency II;
 - informing the Board and keeping the Board updated on the reliability of calculation and on any changes that may be required; in particular, without limitation, the analysis of the movement in technical provisions, including the comparison of best estimates against experience.
2. Express an opinion on the underwriting policy (and other Risk related Policies) and the adequacy of any reinsurance arrangements;
 3. Provide advice and support on the introduction of any new products or amendments of existing products that may materially affect the overall risk profile of the Company and/or its profitability;
 4. Provide advice and support to the Company in the Risk Management system, in particular on the ORSA process, including financial consequences of stresses and scenarios and the modelling risk in respect of ORSA and Minimum Capital Requirements (“MCR”)/SCR calculations.

The Head of Actuarial Function plays an active role within the Company’s organisation. On regular basis, currently monthly, a specific meeting is held at Company’s head office when the senior management (usually CEO; CRO and CFO) share with the HoAF any update in relation to the ongoing obligation of the Company with reference to reporting towards the Supervisory Authority, to the Board and the Committees. He is also regularly invited to the Risk Committees and to the Board where actuarial and Solvency II matters are discussed. Aside of the above mentioned regular meeting, whenever the Company is exploring to introduce new features to the existing products or establish new ones, an ad-hoc meeting is convened to address any matters arising.

B.10 Outsourcing

The Company has chosen to outsource some of its functions and activities to take advantage of economies of scale and external expertise.

Resorting to outsourcing also allows the Company to have more flexibility in resources to be allocated for the proper discharge of the activities and for the assessment of quality of the service performed, with the possibility of a prompt but controlled replacement where needed, thus relieving the risk of any disruption or discontinuation in certain areas of activity. The Company currently outsources the following activities:

Actuarial	Milliman
Internal Audit	Azimut Group
Fund administration activities	Objectway
Policy administration activities	DST – formerly IFDS Percana (until 31/12/2017) Previnet (from 1/1/2018)
IT	Sint IT Services S.A.
Secretarial Services	Matsack Trust
Staff and Payroll	Jefferson

All the above service providers are based in the EU (except Sint IT that is in Switzerland).

B.11 Adequacy of the System of Governance

Reviews of the corporate governance and effectiveness of the Board and its Committees have taken place in 2017. The Company has experienced significant and rapid growth and change and has undertaken and is committed to continue considering the adequacy of its system of governance on an ongoing basis, to consolidate and ensure at all times a sustainable growth of the business.

C. RISK PROFILE

The Company operates a low-risk business model that is supported by a robust Risk Management Framework that ensures risks are well understood and controlled. This is facilitated by the semi-annual quantification of all risks and a culture that promotes the importance of risk management. Integral to this is a thorough understanding and articulation of the Company's risk exposures.

The Company's current strategy is to provide life assurance products on a freedom of establishment basis in Italy. The Company's exposure to the most relevant risks are considered in the following points, whilst the death benefit element is predominately ceded to reinsurers according to the current reinsurance agreements.

The Company focuses on increasing income by increasing the net assets under management. This involves generating new business whilst the increase of the insurance lapse ratio reduces them. The Company does not aim to take on any liquidity risk and so maintains appropriate capital assets and actions to cover this. However, the treatment of the Italian tax prepayment combined with high sales of a certain product requires a closer monitor by the Company on product mix and liquidity risk. This combination of factors could impact on the capability of the Company to pay dividends.

Under normal conditions, the Company has a minimum target on the Solvency II ratio, that is set to 150%. The Solvency II ratio is calculated on a regular basis for regulatory requirements but is also tested on a number of different scenarios within the ORSA process, mainly to understand the consequences of adverse developments in the Company's risk profile. All scenarios tested assume no dividends are paid by the Company.

The Solvency II ratio of the Company is resilient over a number of different scenarios tested within the ORSA, showing relatively narrow changes from the base position.

An overview of the principal risks associated with the business including an outline of how they are each managed is provided below.

C.1 Underwriting Risk

Lapse Risk

The risk that a higher (including mass events) than expected rate of lapses reduces the income generated by the Company. The Lapse SCR as of end of 2017 is €81.8 million, before diversification with other underwriting risks.

Lapses are affected by competition, investment returns and changes in regulation amongst other things.

The Company's products generate positive annual income and hence give rise to an asset (technically a negative provision) on the Solvency II balance sheet in respect of the capitalised value of the projected future profit stream. This suggests that the adverse direction for lapses would be an increase. Both the immediate annual income and the capitalised value of projected future income would be reduced by an increase in lapses, especially a mass lapse one. However, the majority of the expenses would also be proportionally reduced and recoveries would be made also from the tax prepayment. In addition, although the own funds would decrease due to the fall in the capitalised value of future profits, the Company's SCR would also decrease due to the reduction in the amount of the future profit asset at risk. Stresses on increase and decrease of lapses are performed by the Company.

Mortality Risk

The risk that the experienced mortality is higher than expected causing higher cash outflows. The mortality SCR as of the end of 2017 is €4.4 million.

The Company has a limited exposure to mortality risk as the level of death benefit offered is relatively low at present and a significant part of the risk is ceded to a primary reinsurer.

Expense Risk

The expense risk is the possibility that unexpected relevant expenses will materialise. The Expense SCR as of the end of 2017 is €6.1 million.

The Company outsources policyholder and fund administration at a competitive cost. The Company changed policy administration service provider from the 1st January 2018. The new agreement is expected to generate cost saving and to increase the operational efficiency. Nevertheless, any costs increase is not expected to materially change the Company's profitability.

C.2 Market Risk

Market risk arises from potential changes in market rates, prices or liquidity in various markets such as interest rates, real estate, currency, common shares and commodities. The Market SCR as of the end of 2017, after diversification among market risks, is €68.7 million.

The Company's business is 100% unit-linked without guarantees and there is no mismatching between assets and liabilities. The assets are invested according to the fund's investment policy.

Whilst a fall in AUM would reduce both immediate income and the capitalised value of the projected future income stream, it would also reduce some of the expenses and the associated SCR, so would not have a significant impact on solvency.

C.3 Credit Risk

The risk that some or all of the monies owed to the Company may remain unpaid or be paid in part and/or with a considerable delay. The Counterparty SCR as of the end of 2017 is €3.3 million. Credit risk for the Company is limited to banking relationships, policyholders' exit tax prepayments made to the Italian Tax Authority, reinsurance and management of its own funds. The Company invests the vast majority of such assets in highly liquid and secure Government bonds. The Company has credit

concentration risk, mainly due to its key asset being the prepayment of policyholders' exit tax paid to Italian Tax Authority. The level of concentration is higher at payment date and decreases during the remaining months between payment dates.

C.4 Liquidity Risk

A lack of liquidity within the Company may both prevent the Company from being able to pay its obligations as amounts fall due. Such outcomes will clearly limit the ability of the Company to continue as a going concern and write new business.

The Company's Liquidity Policy requires sufficiently held liquid assets to be held to meet cash outflows. Significant operating cash outflows to third parties are the commissions payable to its outsourced service providers and to the distribution networks in relation to their distribution activities. In both cases the amounts are percentages of the income received and so don't affect liquidity.

The Company's dividend policy is flexible and no dividend was paid in some years. This enables the Company to retain cash for liquidity purposes. It is important to underline that the impact of Italian tax prepayment asset, thanks to the decreasing cap will ease dramatically from the next years.

The CFO of the Company is monitoring the liquidity projections on a monthly basis and reports the liquidity projection on a quarterly basis to the Board to keep under control the risk. In addition, the CRO reports regularly to the Risk & Compliance Committee on product mix and liquidity matters.

C.5 Operational Risk

The Solvency II Directive defines 'operational risk' as "the risk of loss arising from inadequate or failed internal processes, personnel or systems, or from external events". The capital requirement for operational risk is therefore calculated using the formula specified in Article 204 of the Delegated Regulations, which for the Company equates to 25% of the amount of expenses incurred during the previous 12 months. The Operational SCR as of the end of 2017 is €2.2 million.

The process through which the Company's operational risk universe is determined and subsequent estimates of frequency and severity are assessed in captured in the Operational Risk Policy. The process safeguards the ongoing improvement of the control environment and ensures that operational risk is identifiable and mitigated as the Company grows.

The Company relies on the use of external parties to provide some services, for example policyholder administration with DST (until the 31st December 2017) and Previnet (from the 1st January 2018), and Objectway. The Company is therefore exposed to potential failure of these outsourcing partners. Such arrangements are closely monitored by the Company's Risk and Compliance Function(s) in accordance with the Outsourcing Policy.

The Company has identified cyber risk as a key risk category where financial loss, disruption or damage to the reputation of the Company from some sort of failure of its information technology systems might be possible.

The Company is endowed with various systems and levels of protection that significantly mitigate this risk (including without being limited to back up activities, cyber-attack protection and cyber threat monitoring, business continuity and disaster recovery, antivirus, antimalware and antispyware, authentication systems etc.). In particular DST and Previnet (the policy administrators) and ObjectWay (the fund administrator), as well as the Company have in place a disaster recovery plan.

C.5 Other Material Risks

There are many risks that face the Company in its day to day activities. To identify and keep track of the risks, the CRO maintains a detailed risk register. In addition to the key risks identified previously the Company considers the following risk to be important:

Capital Requirement Risk

The risk the Company does not have enough capital to cover the regulatory requirements.

The Company has a strong Capital position and the profitability of the Company with the ability to retain the annual profits helps the Company to have an adequate capital. All the scenario tested within the ORSA show that the resilience of the Company's Solvency II ratio.

Strategy Business Model Risk

The risk that the strategy of the Company becomes obsolete, too risky or unprofitable.

The Company has a low risk and prudent strategy to minimize the risk that wrong decision affect the business solidity. Also Azimut Holding has a long term strategy focused to align the needs of clients and financial consultants.

Reputational Risk

The risk that an event could impact the reputation of the Company.

The Company is continuously focused on reputation risks that is robustly managed thanks to the different level of controls to minimize errors that could imply an impact on the reputation.

Governance Risk

The risk that insufficient or inadequate governance arrangements could prohibit the compliance of the Company.

As a result of increased growth over the last years the Company has increased efforts and resources in the area of governance by reinforcing the quality and quantity of individuals involved in the function.

Business Continuity

The risk that an unexpected event affects the Company's ability to manage the business.

The Company has in place various measures to mitigate this kind of risk, such as business continuity and disaster recovery plan including frequent server back-ups that compliment similar plans in place with outsourced serviced providers.

Key Person

The risk of a sudden or unexpected departure of one or more key persons.

The Company has in place a succession plan to mitigate such risk. There is also the possibility to ask to the Holding to support in case of need for the necessary period to find the resources.

Cyber Risk

The risk of financial loss, disruption or damage to the company reputation due to a failure, or unauthorized access, of information technology systems.

The Company has in place robust protection to mitigate as much as possible such risk. Such arrangements are routinely tested by independent security analysts.

C.7 Other Information

Prudent Person Investment

The Company does not provide products where investment performance depends on a structured financial instrument and in general does not invest in structured products, or in illiquid assets.

The use of derivative instruments is permitted. They are mainly future, used with the purpose of hedging the risk of the internal fund.

In every case the Company is following the “Prudent Person Principle” managing the asset of the clients and its own funds.

Risk Sensitivity

The Company performed its second ORSA in 2017 considering the impact of a series of different stress tests, as approved by the Board, to evaluate the Company’s Solvency capability and the liquidity level of the Company under certain scenarios.

All stress tests gave a favourable result regarding the Company’s solvency position. In all instances results were over the minimum Solvency margin cover target of 150% set by the Company.

Regarding liquidity, due to the advance payment to the Italian Tax Authority of the Withholding Tax to be applied to policyholders capital gains (IWT), for a limited period as per one of the scenarios the Company might suffer a possible lack of liquidity. To mitigate this risk the Company is actively acting to achieve an equilibrated mix of new business as occurred in 2016 and 2017. It is to be borne in mind that owing to the strong Solvency position of the Company, in instances of a temporary lack of liquidity the Company has many options available, in accordance with its Liquidity Policy. Such measures include, but are not limited to, a short-term loan from a bank, access to a “financial reinsurance” or an increase of capital from its shareholder.

D. VALUATION FOR SOLVENCY PURPOSE

The Company has one line of business only, single premium unit-linked whole of life products, for the purpose of regulatory reporting. A summary balance sheet as at 31 December 2017 is reported below and presented in accordance with regulatory reporting framework.

Amount in €/000	Section	Financial Statements		QRTs Code
		31/12/2017	Solvency II Value	
ASSETS				
Deferred acquisition costs		2,414		R0020
Intangible assets		158		R0030
Property, plant & equipment held for own use	D.1.1	37	37	R0060
Government Bonds	D.1.2	574	574	R0140
Deposit other than cash equivalents	D.1.3	5,506	5,506	R0200
Assets held for index-linked and unit-linked contracts	D.1.4	6,700,283	6,700,283	R0220
Reinsurance recoverables from Life index-linked and unit-linked	D.1.5		(4,050)	R0340
Insurance and intermediaries receivables	D.1.6	3,795	3,795	R0360
Receivables (trade, not insurance)	D.1.7	124,731	124,731	R0380
Cash and cash equivalents	D.1.8	22,607	22,607	R0410
Any other assets, not elsewhere shown		113	113	R0420
Total assets		6,860,218	6,853,596	R0500
LIABILITIES				
Technical provisions calculated as a whole	D.2		6,700,283	R0700
Best Estimate Liability	D.2		(199,473)	R0710
Risk margin	D.2		34,295	R0720
Technical provisions - index-linked and unit-linked		6,700,283	6,535,105	R0690
Deferred tax liabilities	D.3.1	9	21,108	R0780
Insurance & intermediaries payables	D.3.2	10,071	10,071	R0820
Reinsurance payables	D.3.3	201	201	R0830
Payables (trade, not insurance)	D.3.4	32,664	32,664	R0840
Any other liabilities, not elsewhere shown	D.3.5	2,414		R0880
Total liabilities		6,745,642	6,599,149	R0900
Excess of assets over liabilities		114,576	254,447	R1000

D.1 Assets

The valuation methodology of each type of asset within the regulatory balance sheet reported above is described within the respective section.

The Solvency II Balance Sheet does not include the following assets:

- Intangible Assets
- Financial and operating leases
- Deferred Acquisition Costs
- Deferred Insurance Liabilities

D.1.1 Property, plant and equipment

The amount of such assets is not material and refers to computer and office equipment used for the purpose of the business.

D.1.2 Government Bonds

The Government Bonds are valued at fair value using the quoted price in active market for the same asset.

D.1.3 Deposit other than cash equivalents

The Deposit other than cash equivalents are recognised at nominal value which is an appropriate approximation of the fair value.

D.1.4 Assets held for index-linked and unit-linked contracts

The value of the unit-linked internal funds issued related to the contracts issued by the Company is strictly based on the fair value of the underlying financial assets of each of them.

The measurement basis of the assets' fair value has been categorised into a fair value hierarchy as follows:

- Level 1 – Inputs to Level 1 fair values are quoted prices (unadjusted) in active markets for identical assets.
- Level 2 – Inputs to Level 2 fair values are inputs other than quoted prices included within Level 1 that are observable for the asset, either directly or indirectly
- Level 3 – the fair value is derived from valuation technique

Amounts in €/000	2017
Level 1	544,943
- Government Bonds	7,275
- Open Derivative Positions	1,118
- Shares	126,171
- ETF/ETC	409,379
Level 2	5,648,584
- Mutual Funds	5,618,281
- Corporate Bonds	30,304
Level 3	-
	6,192,527

This asset category also includes an amount of cash equal to € 507,756k.

D.1.5 Reinsurance recoverables from: Life index-linked and unit-linked

The reinsurance recoverable is equal to the expected present value of future cashflows to be paid to and received from the reinsurer, including reinsurance profit share payments. As at 31 December 2017, the reinsurance recoverable was € (4,050)k.

D.1.6 Insurance and intermediaries receivables

The insurance and intermediaries receivable are non-derivative assets with fixed or determinable payments that are not quoted in an active market, which are held at an amount that is an appropriate approximation of the fair value.

D.1.7 Receivables (trade, not insurance)

These receivables assets are non-derivative assets with fixed or determinable payments that are not quoted in an active market, which are held at an amount that is an appropriate approximation of the fair value. The amount also includes €110.1 million as Italian prepayment tax asset.

D.1.8 Cash and cash equivalents

Cash and cash equivalent include cash deposited with banks and held at call.

D.2 Technical Provision

Technical provisions includes the Best Estimate Liabilities (“BEL”) and the Risk Margin. As reported above, AZ Life has a single material line of business, single premium unit-linked whole of life products. The table below reports the two components.

Amount in €/000	UL business
Technical provisions calculated as a whole	6,700,283
Best Estimate Liability	(199,473)
Risk margin	34,295
Technical provisions - index-linked and unit-linked	6,535,105

Best Estimate Liability

The BEL is the expected present value, discounting at the risk-free rate, of the probability-weighted average projected future cash-flows.

The calculations have been performed on a best estimate in accordance with Articles 75 to 86 of the Solvency II Directive. With the exception of a stochastic evaluation of the contribution to the technical provisions from future performance fees, the BEL has been calculated on a deterministic best-estimate basis, with cashflows projected over an 80 year term.

The calculations do not make any allowance for transitional measures or assumed management actions.

Risk Margin

The risk margin is the cost of holding some of the components of the SCR over the lifetime of the obligations, with the cost of capital rate set at 6%. The projection of the SCR is the key input to this calculation.

It also represents an addition to BEL to ensure that technical provisions as a whole are equivalent to the amount required by the Company to meet insurance obligations.

The technical provisions in the financial statements are shown as the technical provisions for linked liabilities amount to a total of €6,700,283k. The difference between the technical provisions in the valuation for solvency and the financial statements (€6,535,105k) is the amount of the risk margin and the difference between the unit-linked liability and the BEL. The difference amounts to €165 million.

The reasons for the difference is the difference between IFRS and the Solvency II regime.

The technical provisions represent a realistic estimate of the Company’s future obligations with an allowance for some deviation for plausible changes in the estimates in the form of the risk margin. They are expected to be sufficient to meet the Company’s obligations in all scenarios.

The Company does not apply the matching adjustment and volatility adjustment referred to in Article 77b and 77d, respectively, of Directive 2009/138/EC.

The Company does not apply the transitional risk-free interest rate-term structure and transitional deduction referred to Article 308c and 308d, respectively, of Directive 2009/138/EC.

The following changes have been made to the calculation of the technical provisions in order to model some items more accurately instead of using approximations:

- Performance fees: the impact on this year calculation was to increase the Present Value of Future Profit (or reduce the BEL) by €25.1 million on the opening balance. Such increase also gave rise to an increase in the SCR calculation, and, by extension, the Risk Margin, which increased by approximately €4 million. The impact at 31st December 2017 was to reduce the BEL by €33.3 million.
- Surrender charges & Death Benefit: the more accurate modelling of the death benefit and the inclusion of the surrender charges (for Pleiadi product) within the calculation of the BEL resulted in an increase of the PVFP (or reduction in BEL) of €0.5 million.
- Reinsurance Profit Share: such specific agreement came into force in 2017 and resulted in €5.2 million of reduction of the negative reinsurance asset.

D.3 Other Liabilities

D.3.1 Deferred Tax Liabilities

Deferred tax are computed in respect of the timing differences arising between the tax base of assets and liabilities and their carrying amounts in the financial statements, applying the tax rates in force in the years in which the aforementioned differences are expected to reverse.

Deferred tax assets are recorded when there is reasonable certainty they will be recovered, i.e. to the extent that the company is expected to generate sufficient taxable income in the future to be able to recover the taxes paid.

As the BEL is calculated as considering the present value of the future cashflows of the Company, which is assumed to be equal to the future taxable profit, the deduction from the total value of unit funds increases AZ Life's own funds compared to the statutory accounts basis, which is used to determine corporate tax. This impact is partly offset by the introduction of the risk margin.

The combined impact of these adjustments is about €161 million net of reinsurance recoverables and increase in AZ Life's own funds as at 31 December 2017. A deferred tax liability of €21.1 million is set up on the Solvency II balance sheet in respect of this increase, reflecting the increase in own funds multiplied by the effective corporation tax rate (13.15% as at 31 December 2017).

D.3.2 Insurance & intermediaries payables

Financial liabilities are initially measured at fair value net of transaction costs. These are subsequently measured at amortised cost using the effective interest method, with interest expense recognised on an effective yield basis, which is equal to the fair value.

D.3.3 Reinsurance payables

The value of these payables has been determined in accordance with the section D.3.2.

D.3.4 Payables (trade, not insurance)

The value of these payables has been determined in accordance with the section D.3.2.

D.3.5 Others

AZ Life does not have any financial or operating leases as explained in section D.1 and does not have any liabilities for employee benefits. Accordingly, no disclosure has been made.

The deferred income liabilities have not been considered under the Solvency II.

D.4 Alternative methods of valuation

AZ Life does not use any alternative methods for valuation.

D.5 Any other information

There is no additional material information regarding the valuation of assets and liabilities for solvency purposes.

E. CAPITAL MANAGEMENT

E.1 Own Funds

E.1.1 Objectives, policies and processes employed for managing own funds

The Company has a single shareholder, Azimut Holding SpA, and the called up capital is fully paid up. AZ Life has no debt financing nor does it have any plans to raise debt or issue new shares in the short or medium term.

The Company's own funds are primarily invested in cash deposits in bank accounts and Government Bond. There is no intention to change the disposition of own fund items.

The Capital Management policy approved by the Board whereby a provision to maintain a minimum level of Solvency Margin equal to the 150% of the SCR has been included.

In addition, a minimum buffer of cash amount, set up within the Liquidity Risk Management Policy, should be kept at all time to face any potential liquidity shortfall. No capital is planned to be issued in the short or medium term.

On an annual basis, and having regarded to the results of stress tests applied to projections over the planning period included within the ORSA process, the Board will consider whether a dividend should be paid to remit any surplus of the capital over the level of mentioned above, having taken into consideration the liquidity needs.

E.1.2 Analysis and details of own funds items

The table below reports the movements of the own funds items during the year.

Amount in €/000	2016	2017
Tier 1 unrestricted at beginning of the year		
Ordinary share capital (gross of own shares)	650	650
Other own fund items approved by the supervisory authority as basic own funds not specified above		9,350
Reconciliation reserve	165,473	181,587
Total Own Funds to cover SCR and MCR	166,123	191,857
Tier 1 unrestricted at the end of the year		
Ordinary share capital (gross of own shares)	650	650
Other own fund items approved by the supervisory authority as basic own funds not specified above	9,350	9,350
Reconciliation reserve	181,587	244,447
Total Own Funds to cover SCR and MCR	191,587	254,447
SCR	86,722	109,018
Ratio SCR	221%	234%
MCR	39,025	45,548
Ratio MCR	491%	559%

The additional item classified as Tier 1 unrestricted for the amount of €9,350k relates to the amount of all the capital contributions, for which the approval of such classification has been received from the CBI.

Such table reports the information in relation to the structure, amount and quality of own funds as of 31 December 2017, compared to the same structure of the previous year. It also includes the eligible amount of own funds to cover SCR and MCR classified by tier.

The reconciliation reserve represents retained profits and the difference between technical provisions for solvency purposes and the liabilities to customers under investment and insurance contracts reported in the financial statements.

The increase of the Reconciliation reserve is mainly deriving from the increase of the BEL due to additional assets arising on new business sold and top-ups during the year. Significant part of such increase is for the contribution from the sales of AZ Navigator product.

E.1.3 Material differences between equity as shown in AZ Life's financial statements and the excess of assets over liabilities as calculated for solvency purposes

The difference between the Company's equity as reported within the audited financial statements and the Solvency II own funds above is due to the BEL impact, risk margin, reinsurance asset and Solvency II deferred tax adjustment (see section D for further information on these items).

E.1.4 Basic own funds subject to transitional arrangements

No own funds of the Company are subject to transitional arrangements

E.1.5 Ancillary own funds

No ancillary own funds are included within the own funds amount.

E.1.6 Items deducted from own funds

No deductions have been applied to own funds and there are no significant restrictions affecting their availability and transferability.

E.1.7 Own funds

AZ Life does not have additional ratios to the ones included in template S.23.01.

E.2 Solvency Capital Requirement and Minimum Capital Requirement

E.2.1 SCR and MCR – Year End 2016-2017

Amount in €/000	2016	2017
Capital Requirement		
SCR	86,722	109,018
MCR	39,025	45,548

E.2.2 SCR Split by risk module

AZ Life's components of the SCR, calculated using the Standard Formula, are detailed within the table below and compared to last year figures.

Amount in €/000	2016	2017
Market Risk	53,233	68,714
Counterparty Default Risk	7,305	3,307
Life Risk	66,871	85,337
Diversification	(29,545)	(34,063)
Basic Solvency Capital Requirement	97,865	123,295
Calculation of Solvency Capital Requirement		
Operational Risk	1,930	2,157
Loss-absorbing capacity of deferred taxes	(13,073)	(16,434)
Solvency Capital Requirement	86,722	109,018

E.2.3 Standard Formula Simplification

The Company is not using any Standard Formula simplifications.

E.2.4 Specific parameters of the Standard Formula

The Company is not using any undertaking specific parameters.

E.2.5 Capital Add-ons

AZ Life does not have any capital add-ons or specific parameters applied to the SCR calculation.

E.2.6 MCR Input

AZ Life MCR at 31 December 2017 is capped at €49,058k, being 45% of the SCR.

The linear MCR is calculated as 0.7% of the index-linked and unit-linked obligations. The combined MCR is calculated as the lower of;

- The maximum of the linear MCR and MCR floor
- MCR cap which is 45% of the SCR

Company's MCR is set at linear MCR value, being lower than the MCR cap of 45% of the SCR.

E.3 Use of the duration-based equity risk sub-module in the calculation of the Solvency Capital Requirement

AZ Life does not use the duration-based equity risk sub-module in the calculation of its SCR.

E.4 Internal Model Information

AZ Life is using the standard formula to calculate the Solvency Capital Requirement, so internal model is not used.

E.5 Non-compliance with the Minimum Capital Requirement and noncompliance with the Solvency Capital Requirement

AZ Life's capital exceeds both the MCR and the SCR throughout the reporting period.

E.6 Any other information

There is no additional information in relation to the capital management of the Company.

APPENDIX 1 – REPORTING TEMPLATES

The table below reports the quantitative reporting templates (QRTs) to be included within the SFCR.

QRT Code	QRT Name	Reported / Not Reported
S.02.01.02	Balance sheet	Reported
S.05.01.01	Premiums, claims and expenses by line of business	Reported
S.05.02.01	Premiums, claims and expenses by country	Reported
S.12.01.02	Life and Health SLT Technical Provisions	Reported
S.17.01.02	Non-Life Technical Provisions	Not Reported
S.19.01.21	Non-Life insurance claims	Not Reported
S.22.01.21	Impact of long term guarantees and transitional measures	Not Reported
S.23.01.01	Own funds	Reported
S.25.01.21	Solvency Capital Requirement - for undertakings on Standard Formula	Reported
S.25.02.21	Solvency Capital Requirement - for undertakings using the standard formula and the partial internal model	Not Reported
S.25.03.21	Solvency Capital Requirement - for undertakings on Full Internal Models	Not Reported
S.28.01.01	Minimum Capital Requirement - Only life or only non-life insurance or reinsurance activity	Reported
S.28.02.01	Minimum Capital Requirement - Both life and non-life insurance activity	Not Reported

APPENDIX: ANNUAL QUANTITATIVE REPORTING TEMPLATES

(Amount in €/000)

QRTs: S.02.01.02 – Balance Sheet

Assets		Solvency II value - C0010
Intangible assets	R0030	0.0
Deferred tax assets	R0040	0.0
Pension benefit surplus	R0050	0.0
Property, plant & equipment held for own use	R0060	36.9
Investments (other than assets held for index-linked and unit-linked contracts)	R0070	6,079.3
Property (other than for own use)	R0080	0.0
Holdings in related undertakings, including participations	R0090	0.0
Equities	R0100	0.0
Equities - listed	R0110	0.0
Equities - unlisted	R0120	0.0
Bonds	R0130	573.7
Government Bonds	R0140	573.7
Corporate Bonds	R0150	0.0
Structured notes	R0160	0.0
Collateralised securities	R0170	0.0
Collective Investments Undertakings	R0180	0.0
Derivatives	R0190	0.0
Deposits other than cash equivalents	R0200	5,505.6
Other investments	R0210	0.0
Assets held for index-linked and unit-linked contracts	R0220	6,700,283.3
Loans and mortgages	R0230	0.0
Loans on policies	R0240	0.0
Loans and mortgages to individuals	R0250	0.0
Other loans and mortgages	R0260	0.0
Reinsurance recoverables from:	R0270	-4,050.1
Non-life and health similar to non-life	R0280	0.0
Non-life excluding health	R0290	0.0
Health similar to non-life	R0300	0.0
Life and health similar to life, excluding health and index-linked and unit-linked	R0310	0.0
Health similar to life	R0320	0.0
Life excluding health and index-linked and unit-linked	R0330	0.0
Life index-linked and unit-linked	R0340	-4,050.1
Deposits to cedants	R0350	0.0
Insurance and intermediaries receivables	R0360	3,795.1
Reinsurance receivables	R0370	0.0
Receivables (trade, not insurance)	R0380	124,731.1
Own shares (held directly)	R0390	0.0
Amounts due in respect of own fund items or initial fund called up but not paid	R0400	0.0
Cash and cash equivalents	R0410	22,607.4
Any other assets, not elsewhere shown	R0420	113.3
Total assets	R0500	6,853,596.2

Liabilities		Solvency II value - C0010
Technical provisions – non-life	R0510	0.0
Technical provisions – non-life (excluding health)	R0520	0.0
Technical provisions calculated as a whole	R0530	0.0
Best Estimate	R0540	0.0
Risk margin	R0550	0.0
Technical provisions - health (similar to non-life)	R0560	0.0
Technical provisions calculated as a whole	R0570	0.0
Best Estimate	R0580	0.0
Risk margin	R0590	0.0
Technical provisions - life (excluding index-linked and unit-linked)	R0600	0.0
Technical provisions - health (similar to life)	R0610	0.0
Technical provisions calculated as a whole	R0620	0.0
Best Estimate	R0630	0.0
Risk margin	R0640	0.0
Technical provisions – life (excluding health and index-linked and unit-linked)	R0650	0.0
Technical provisions calculated as a whole	R0660	0.0
Best Estimate	R0670	0.0
Risk margin	R0680	0.0
Technical provisions – index-linked and unit-linked	R0690	6,535,105.2
Technical provisions calculated as a whole	R0700	6,700,283.3
Best Estimate	R0710	-199,472.6
Risk margin	R0720	34,294.6
Contingent liabilities	R0740	0.0
Provisions other than technical provisions	R0750	0.0
Pension benefit obligations	R0760	0.0
Deposits from reinsurers	R0770	0.0
Deferred tax liabilities	R0780	21,107.8
Derivatives	R0790	0.0
Debts owed to credit institutions	R0800	0.0
Financial liabilities other than debts owed to credit institutions	R0810	0.0
Insurance & intermediaries payables	R0820	10,071.6
Reinsurance payables	R0830	200.6
Payables (trade, not insurance)	R0840	32,663.8
Subordinated liabilities	R0850	0.0
Subordinated liabilities not in Basic Own Funds	R0860	0.0
Subordinated liabilities in Basic Own Funds	R0870	0.0
Any other liabilities, not elsewhere shown	R0880	0.0
Total liabilities	R0900	6,599,149.0
Excess of assets over liabilities	R1000	254,447.2

QRTs: S.05.02.01 – Premiums, claims and expenses by country

		Home Country	Top 5 countries (by amount of gross premiums written - Life obligations)	Total Top 5 and home country
		C0150	C0160	C0210
	R1400		IT	
		C0220	C0230	C0280
Premiums written				
Gross	R1410	0.0	1,525,922.9	1,525,922.9
Reinsurers' share	R1420	0.0	2,544.4	2,544.4
Net	R1500	0.0	1,523,378.5	1,523,378.5
Premiums earned				
Gross	R1510	0.0	1,525,922.9	1,525,922.9
Reinsurers' share	R1520	0.0	2,544.4	2,544.4
Net	R1600	0.0	1,523,378.5	1,523,378.5
Claims incurred				
Gross	R1610	0.0	1,244,232.2	1,244,232.2
Reinsurers' share	R1620	0.0	270.8	270.8
Net	R1700	0.0	1,243,961.4	1,243,961.4
Changes in other technical provisions				
Gross	R1710	0.0	-169,585.7	-169,585.7
Reinsurers' share	R1720	0.0	0.0	0.0
Net	R1800	0.0	-169,585.7	-169,585.7
Expenses incurred	R1900	0.0	10,614.1	10,614.1
Other expenses	R2500			0.0
Total expenses	R2600			10,614.1

QRTs: S.12.01.02 – Life and Health SLT Technical Provisions

		Insurance with profit participation	Index-linked and unit-linked insurance		Other life insurance			Annuities stemming from non-life insurance contracts and relating to insurance obligation other than health insurance obligations	Accepted reinsurance	Total (Life other than health insurance, incl. Unit-Linked)	Health insurance (direct business)		Annuities stemming from non-life insurance contracts and relating to health insurance obligations	Health reinsurance (reinsurance accepted)	Total (Health similar to life insurance)		
			Contracts without options and guarantees	Contracts with options or guarantees	Contracts without options and guarantees	Contracts with options or guarantees	Contracts without options and guarantees				Contracts with options or guarantees						
		C0020	C0030	C0040	C0050	C0060	C0070	C0080	C0090	C0100	C0150	C0160	C0170	C0180	C0190	C0200	C0210
Technical provisions calculated as a whole	R0010	0.0	6,700,283.3			0.0			0.0	0.0	6,700,283.3	0.0			0.0	0.0	0.0
Total recoverable from reinsurance/SPV after the adjustment for expected losses due to counterparty default	R0020	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Technical provisions calculated as a sum of BE and RM																	
Best Estimate																	
Gross Best Estimate	R0030	0.0		-199,472.6	0.0		0.0	0.0	0.0	0.0	-199,472.6		0.0	0.0	0.0	0.0	0.0
Total recoverables from reinsurance/SPV and Finite Re before the adjustment for expected losses due to counterparty default	R0040	0.0		-4,050.1	0.0		0.0	0.0	0.0	0.0	-4,050.1		0.0	0.0	0.0	0.0	0.0
Recoverables from reinsurance (except SPV and Finite Re) before adjustment for expected losses	R0050	0.0		-4,050.1	0.0		0.0	0.0	0.0	0.0	-4,050.1		0.0	0.0	0.0	0.0	0.0
Recoverables from SPV before adjustment for expected losses	R0060	0.0		0.0	0.0		0.0	0.0	0.0	0.0	0.0		0.0	0.0	0.0	0.0	0.0
Recoverables from Finite Re before adjustment for expected losses	R0070	0.0		0.0	0.0		0.0	0.0	0.0	0.0	0.0		0.0	0.0	0.0	0.0	0.0
Total Recoverables from reinsurance/SPV and Finite Re after the adjustment for expected losses due to counterparty default	R0080	0.0		-4,050.1	0.0		0.0	0.0	0.0	0.0	-4,050.1		0.0	0.0	0.0	0.0	0.0
Best estimate minus recoverables from reinsurance/SPV and Finite Re	R0090	0.0		-195,422.6	0.0		0.0	0.0	0.0	0.0	-195,422.6		0.0	0.0	0.0	0.0	0.0
Risk Margin	R0100	0.0	34,298.4			0.0			0.0	0.0	34,298.4	0.0			0.0	0.0	0.0
Amount of the transitional on Technical Provisions																	
Technical provisions calculated as a whole	R0110	0.0	0.0			0.0			0.0	0.0	0.0	0.0			0.0	0.0	0.0
Best Estimate	R0120	0.0		0.0	0.0		0.0	0.0	0.0	0.0	0.0		0.0	0.0	0.0	0.0	0.0
Risk Margin	R0130	0.0	0.0			0.0			0.0	0.0	0.0	0.0			0.0	0.0	0.0
Technical provisions - total	R0200	0.0	6,535,109.0			0.0			0.0	0.0	6,535,109.0	0.0			0.0	0.0	0.0

QRTs: S.25.01.21 – Solvency Capital Requirement - for undertakings on Standard Formula

		Net solvency capital requirement	Gross solvency capital requirement	Allocation from adjustments due to RFF and Matching adjustments portfolios
		C0030	C0040	C0050
Market risk	R0010	68,714.0	68,714.0	0.0
Counterparty default risk	R0020	3,306.5	3,306.5	0.0
Life underwriting risk	R0030	85,337.1	85,337.1	0.0
Health underwriting risk	R0040	0.0	0.0	0.0
Non-life underwriting risk	R0050	0.0	0.0	0.0
Diversification	R0060	-34,062.9	-34,062.9	
Intangible asset risk	R0070	0.0	0.0	
Basic Solvency Capital Requirement	R0100	123,294.7	123,294.7	
Calculation of Solvency Capital Requirement		C0100		
Adjustment due to RFF/MAP nSCR aggregation	R0120	0.0		
Operational risk	R0130	2,157.5		
Loss-absorbing capacity of technical provisions	R0140	0.0		
Loss-absorbing capacity of deferred taxes	R0150	-16,434.2		
Capital requirement for business operated in accordance with Art. 4 of Directive 2003/41/EC	R0160	0.0		
Solvency Capital Requirement excluding capital add-on	R0200	109,018.0		
Capital add-on already set	R0210	0.0		
Solvency capital requirement for undertakings under consolidated method	R0220	109,018.0		
Other information on SCR				
Capital requirement for duration-based equity risk sub-module	R0400	0.0		
Total amount of Notional Solvency Capital Requirements for remaining part	R0410	0.0		
Total amount of Notional Solvency Capital Requirements for ring fenced funds	R0420	0.0		
Total amount of Notional Solvency Capital Requirements for matching adjustment portfolios	R0430	0.0		
Diversification effects due to RFF nSCR aggregation for article 304	R0440	0.0		
Method used to calculate the adjustment due to RFF/MAP nSCR aggregation	R0450	4 - No adjustment		
Net future discretionary benefits	R0460	0.0		

QRTs: S.28.01.01 – Minimum Capital Requirement - Only life or only non-life insurance or reinsurance activity

Linear formula component for non-life insurance and reinsurance obligations				
		C0010		
MCRNL Result	R0010	0.0		
			Net (of reinsurance/SPV) best estimate and TP calculated as a whole	Net (of reinsurance) written premiums in the last 12 months
			C0020	C0030
Medical expense insurance and proportional reinsurance	R0020	0.0	0.0	0.0
Income protection insurance and proportional reinsurance	R0030	0.0	0.0	0.0
Workers' compensation insurance and proportional reinsurance	R0040	0.0	0.0	0.0
Motor vehicle liability insurance and proportional reinsurance	R0050	0.0	0.0	0.0
Other motor insurance and proportional reinsurance	R0060	0.0	0.0	0.0
Marine, aviation and transport insurance and proportional reinsurance	R0070	0.0	0.0	0.0
Fire and other damage to property insurance and proportional reinsurance	R0080	0.0	0.0	0.0
General liability insurance and proportional reinsurance	R0090	0.0	0.0	0.0
Credit and suretyship insurance and proportional reinsurance	R0100	0.0	0.0	0.0
Legal expenses insurance and proportional reinsurance	R0110	0.0	0.0	0.0
Assistance and proportional reinsurance	R0120	0.0	0.0	0.0
Miscellaneous financial loss insurance and proportional reinsurance	R0130	0.0	0.0	0.0
Non-proportional health reinsurance	R0140	0.0	0.0	0.0
Non-proportional casualty reinsurance	R0150	0.0	0.0	0.0
Non-proportional marine, aviation and transport reinsurance	R0160	0.0	0.0	0.0
Non-proportional property reinsurance	R0170	0.0	0.0	0.0
Linear formula component for life insurance and reinsurance obligations				
		C0040		
MCRCL Result	R0200	45,547.7		
			Net (of reinsurance/SPV) best estimate and TP calculated as a whole	Net (of reinsurance/SPV) total capital at risk
			C0050	C0060
Obligations with profit participation - guaranteed benefits	R0210	0.0	0.0	
Obligations with profit participation - future discretionary benefits	R0220	0.0	0.0	
Index-linked and unit-linked insurance obligations	R0230	6,504,860.7	6,504,860.7	
Other life (re)insurance and health (re)insurance obligations	R0240	0.0	0.0	
Total capital at risk for all life (re)insurance obligations	R0250			19,597.9
Overall MCR calculation				
		C0070		
Linear MCR	R0300	45,547.7		
SCR	R0310	109,018.0		
MCR cap	R0320	49,058.1		
MCR floor	R0330	27,254.5		
Combined MCR	R0340	45,547.7		
Absolute floor of the MCR	R0350	3,700.0		
		C0070		
Minimum Capital Requirement	R0400	45,547.7		